A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. - Trial NCT06414798
Access comprehensive clinical trial information for NCT06414798 through Pure Global AI's free database. This Phase 1 trial is sponsored by AbbVie and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AbbVie
Timeline & Enrollment
Phase 1
May 13, 2024
Nov 28, 2024
Primary Outcome
Maximum Plasma Concentration (Cmax) of ABBV-1088,Time to Cmax (Tmax) of ABBV-1088,Terminal Phase Elimination Rate Constant (Beta) of ABBV-1088,Terminal Phase Elimination Half-Life (t1/2) of ABBV-1088,Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-1088,Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-1088,Number of Participants With Adverse Events (AEs)
Summary
This study will assess the single dose safety, tolerability and pharmacokinetic properties of
 ABBV-1088 in healthy adult participants
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06414798
Non-Device Trial